Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 113 entries
Sorted by: Best Match Show Resources per page
Poly(alkyl methacrylate) Brush-Grafted Silica Nanoparticles as Oil Lubricant Additives: Effects of Alkyl Pendant Groups on Oil Dispersibility, Stability, and Lubrication Property.

ACS applied materials & interfaces

Seymour BT, Wright RAE, Parrott AC, Gao H, Martini A, Qu J, Dai S, Zhao B.
PMID: 28670899
ACS Appl Mater Interfaces. 2017 Jul 26;9(29):25038-25048. doi: 10.1021/acsami.7b06714. Epub 2017 Jul 12.

This article reports on the synthesis of a series of poly(alkyl methacrylate) brush-grafted, 23 nm silica nanoparticles (hairy NPs) and the study of the effect of alkyl pendant length on their use as oil lubricant additives for friction and...

Cite
Seymour BT, Wright RAE, Parrott AC, et al. Poly(alkyl methacrylate) Brush-Grafted Silica Nanoparticles as Oil Lubricant Additives: Effects of Alkyl Pendant Groups on Oil Dispersibility, Stability, and Lubrication Property. ACS Appl Mater Interfaces. 2017;9(29):25038-25048doi: 10.1021/acsami.7b06714.
Seymour, B. T., Wright, R. A. E., Parrott, A. C., Gao, H., Martini, A., Qu, J., Dai, S., & Zhao, B. (2017). Poly(alkyl methacrylate) Brush-Grafted Silica Nanoparticles as Oil Lubricant Additives: Effects of Alkyl Pendant Groups on Oil Dispersibility, Stability, and Lubrication Property. ACS applied materials & interfaces, 9(29), 25038-25048. https://doi.org/10.1021/acsami.7b06714
Seymour, Bryan T, et al. "Poly(alkyl methacrylate) Brush-Grafted Silica Nanoparticles as Oil Lubricant Additives: Effects of Alkyl Pendant Groups on Oil Dispersibility, Stability, and Lubrication Property." ACS applied materials & interfaces vol. 9,29 (2017): 25038-25048. doi: https://doi.org/10.1021/acsami.7b06714
Seymour BT, Wright RAE, Parrott AC, Gao H, Martini A, Qu J, Dai S, Zhao B. Poly(alkyl methacrylate) Brush-Grafted Silica Nanoparticles as Oil Lubricant Additives: Effects of Alkyl Pendant Groups on Oil Dispersibility, Stability, and Lubrication Property. ACS Appl Mater Interfaces. 2017 Jul 26;9(29):25038-25048. doi: 10.1021/acsami.7b06714. Epub 2017 Jul 12. PMID: 28670899.
Copy Download .nbib Format: NLM
The one neither of us saw .

BMJ (Clinical research ed.)

Seymour A.
PMID: 10356020
BMJ. 1999 Jun 05;318(7197):1552. doi: 10.1136/bmj.318.7197.1552.

No abstract available.

Cite
Seymour A. The one neither of us saw . BMJ. 1999;318(7197):1552doi: 10.1136/bmj.318.7197.1552.
Seymour, A. (1999). The one neither of us saw . BMJ (Clinical research ed.), 318(7197), 1552. https://doi.org/10.1136/bmj.318.7197.1552
Seymour. "The one neither of us saw ." BMJ (Clinical research ed.) vol. 318,7197 (1999): 1552. doi: https://doi.org/10.1136/bmj.318.7197.1552
Seymour A. The one neither of us saw . BMJ. 1999 Jun 05;318(7197):1552. doi: 10.1136/bmj.318.7197.1552. PMID: 10356020; PMCID: PMC1115912.
Copy Download .nbib Format: NLM
Pharmacokinetics and efficacy of low-dose ketoprofen in postoperative dental pain.

Clinical drug investigation

Seymour RA, Kelly PJ, Hawkesford JE.
PMID: 18370482
Clin Drug Investig. 1998;15(4):279-84. doi: 10.2165/00044011-199815040-00003.

A double-blind, randomised trial was carried out to investigate the relationship between efficacy and various pharmacokinetic variables after single doses of racemic ketoprofen 12.5 and 25mg in patients with postoperative pain after third molar surgery over a 4-hour investigation...

Cite
Seymour RA, Kelly PJ, Hawkesford JE. Pharmacokinetics and efficacy of low-dose ketoprofen in postoperative dental pain. Clin Drug Investig. 1998;15(4):279-84doi: 10.2165/00044011-199815040-00003.
Seymour, R. A., Kelly, P. J., & Hawkesford, J. E. (1998). Pharmacokinetics and efficacy of low-dose ketoprofen in postoperative dental pain. Clinical drug investigation, 15(4), 279-84. https://doi.org/10.2165/00044011-199815040-00003
Seymour, R A, et al. "Pharmacokinetics and efficacy of low-dose ketoprofen in postoperative dental pain." Clinical drug investigation vol. 15,4 (1998): 279-84. doi: https://doi.org/10.2165/00044011-199815040-00003
Seymour RA, Kelly PJ, Hawkesford JE. Pharmacokinetics and efficacy of low-dose ketoprofen in postoperative dental pain. Clin Drug Investig. 1998;15(4):279-84. doi: 10.2165/00044011-199815040-00003. PMID: 18370482.
Copy Download .nbib Format: NLM
The Possible Relationship of Mutual Benefit Associations to the Health of Employes.

American journal of public health and the nation's health

Seymour HA.
PMID: 18012658
Am J Public Health Nations Health. 1929 Jan;19(1):16-20. doi: 10.2105/ajph.19.1.16.

No abstract available.

Cite
Seymour HA. The Possible Relationship of Mutual Benefit Associations to the Health of Employes. Am J Public Health Nations Health. 1929;19(1):16-20doi: 10.2105/ajph.19.1.16.
Seymour, H. A. (1929). The Possible Relationship of Mutual Benefit Associations to the Health of Employes. American journal of public health and the nation's health, 19(1), 16-20. https://doi.org/10.2105/ajph.19.1.16
Seymour, H A. "The Possible Relationship of Mutual Benefit Associations to the Health of Employes." American journal of public health and the nation's health vol. 19,1 (1929): 16-20. doi: https://doi.org/10.2105/ajph.19.1.16
Seymour HA. The Possible Relationship of Mutual Benefit Associations to the Health of Employes. Am J Public Health Nations Health. 1929 Jan;19(1):16-20. doi: 10.2105/ajph.19.1.16. PMID: 18012658; PMCID: PMC1580879.
Copy Download .nbib Format: NLM
Precision medicine for all? Challenges and opportunities for a precision medicine approach to critical illness.

Critical care (London, England)

Seymour CW, Gomez H, Chang CH, Clermont G, Kellum JA, Kennedy J, Yende S, Angus DC.
PMID: 29047353
Crit Care. 2017 Oct 18;21(1):257. doi: 10.1186/s13054-017-1836-5.

All of medicine aspires to be precise, where a greater understanding of individual data will lead to personalized treatment and improved outcomes. Prompted by specific examples in oncology, the field of critical care may be tempted to envision that...

Cite
Seymour CW, Gomez H, Chang CH, et al. Precision medicine for all? Challenges and opportunities for a precision medicine approach to critical illness. Crit Care. 2017;21(1):257doi: 10.1186/s13054-017-1836-5.
Seymour, C. W., Gomez, H., Chang, C. H., Clermont, G., Kellum, J. A., Kennedy, J., Yende, S., & Angus, D. C. (2017). Precision medicine for all? Challenges and opportunities for a precision medicine approach to critical illness. Critical care (London, England), 21(1), 257. https://doi.org/10.1186/s13054-017-1836-5
Seymour, Christopher W, et al. "Precision medicine for all? Challenges and opportunities for a precision medicine approach to critical illness." Critical care (London, England) vol. 21,1 (2017): 257. doi: https://doi.org/10.1186/s13054-017-1836-5
Seymour CW, Gomez H, Chang CH, Clermont G, Kellum JA, Kennedy J, Yende S, Angus DC. Precision medicine for all? Challenges and opportunities for a precision medicine approach to critical illness. Crit Care. 2017 Oct 18;21(1):257. doi: 10.1186/s13054-017-1836-5. PMID: 29047353; PMCID: PMC5648512.
Copy Download .nbib Format: NLM
Google Search Trends in Oncology and the Impact of Celebrity Cancer Awareness.

Cureus

Kaleem T, Malouff TD, Stross WC, Waddle MR, Miller DH, Seymour AL, Zaorsky NG, Miller RC, Trifiletti DM, Vallow L.
PMID: 31608195
Cureus. 2019 Aug 10;11(8):e5360. doi: 10.7759/cureus.5360.

Introduction There is widespread public interest when celebrities are diagnosed with cancer. We sought to assess how this interest impacts awareness of prevalent cancers. Methods We reviewed common cancer-related search terms using Google Trends (Google LLC, Mountain View, CA)...

Cite
Kaleem T, Malouff TD, Stross WC, et al. Google Search Trends in Oncology and the Impact of Celebrity Cancer Awareness. Cureus. 2019;11(8):e5360doi: 10.7759/cureus.5360.
Kaleem, T., Malouff, T. D., Stross, W. C., Waddle, M. R., Miller, D. H., Seymour, A. L., Zaorsky, N. G., Miller, R. C., Trifiletti, D. M., & Vallow, L. (2019). Google Search Trends in Oncology and the Impact of Celebrity Cancer Awareness. Cureus, 11(8), e5360. https://doi.org/10.7759/cureus.5360
Kaleem, Tasneem, et al. "Google Search Trends in Oncology and the Impact of Celebrity Cancer Awareness." Cureus vol. 11,8 (2019): e5360. doi: https://doi.org/10.7759/cureus.5360
Kaleem T, Malouff TD, Stross WC, Waddle MR, Miller DH, Seymour AL, Zaorsky NG, Miller RC, Trifiletti DM, Vallow L. Google Search Trends in Oncology and the Impact of Celebrity Cancer Awareness. Cureus. 2019 Aug 10;11(8):e5360. doi: 10.7759/cureus.5360. PMID: 31608195; PMCID: PMC6783227.
Copy Download .nbib Format: NLM
Identifying Clinical Research Priorities in Adult Pulmonary and Critical Care: NHLBI Working Group Report.

American journal of respiratory and critical care medicine

Semler MW, Bernard GR, Aaron SD, Angus DC, Biros MH, Brower RG, Calfee CS, Colantuoni EA, Ferguson ND, Gong MN, Hopkins RO, Hough CL, Iwashyna TJ, Levy BD, Martin TR, Matthay MA, Mizgerd JP, Moss M, Needham DM, Self WH, Seymour CW, Stapleton RD, Thompson BT, Wunderink RG, Aggarwal NR, Reineck LA.
PMID: 32150460
Am J Respir Crit Care Med. 2020 Mar 09; doi: 10.1164/rccm.201908-1595WS. Epub 2020 Mar 09.

Preventing, treating, and promoting recovery from critical illness due to pulmonary disease are foundational goals of the critical care community and the National Heart, Lung, and Blood Institute. Decades of clinical research in acute respiratory distress syndrome, acute respiratory...

Cite
Semler MW, Bernard GR, Aaron SD, et al. Identifying Clinical Research Priorities in Adult Pulmonary and Critical Care: NHLBI Working Group Report. Am J Respir Crit Care Med. 2020;doi: 10.1164/rccm.201908-1595WS.
Semler, M. W., Bernard, G. R., Aaron, S. D., Angus, D. C., Biros, M. H., Brower, R. G., Calfee, C. S., Colantuoni, E. A., Ferguson, N. D., Gong, M. N., Hopkins, R. O., Hough, C. L., Iwashyna, T. J., Levy, B. D., Martin, T. R., Matthay, M. A., Mizgerd, J. P., Moss, M., Needham, D. M., Self, W. H., Seymour, C. W., Stapleton, R. D., Thompson, B. T., Wunderink, R. G., Aggarwal, N. R., & Reineck, L. A. (2020). Identifying Clinical Research Priorities in Adult Pulmonary and Critical Care: NHLBI Working Group Report. American journal of respiratory and critical care medicine, . https://doi.org/10.1164/rccm.201908-1595WS
Semler, Matthew W, et al. "Identifying Clinical Research Priorities in Adult Pulmonary and Critical Care: NHLBI Working Group Report." American journal of respiratory and critical care medicine vol. (2020). doi: https://doi.org/10.1164/rccm.201908-1595WS
Semler MW, Bernard GR, Aaron SD, Angus DC, Biros MH, Brower RG, Calfee CS, Colantuoni EA, Ferguson ND, Gong MN, Hopkins RO, Hough CL, Iwashyna TJ, Levy BD, Martin TR, Matthay MA, Mizgerd JP, Moss M, Needham DM, Self WH, Seymour CW, Stapleton RD, Thompson BT, Wunderink RG, Aggarwal NR, Reineck LA. Identifying Clinical Research Priorities in Adult Pulmonary and Critical Care: NHLBI Working Group Report. Am J Respir Crit Care Med. 2020 Mar 09; doi: 10.1164/rccm.201908-1595WS. Epub 2020 Mar 09. PMID: 32150460; PMCID: PMC7427373.
Copy Download .nbib Format: NLM
Impact of Intravenous Iron on Oxidative Stress and Mitochondrial Function in Experimental Chronic Kidney Disease.

Antioxidants (Basel, Switzerland)

Nuhu F, Seymour AM, Bhandari S.
PMID: 31640237
Antioxidants (Basel). 2019 Oct 21;8(10). doi: 10.3390/antiox8100498.

BACKGROUND: Mitochondrial dysfunction is observed in chronic kidney disease (CKD). Iron deficiency anaemia (IDA), a common complication in CKD, is associated with poor clinical outcomes affecting mitochondrial function and exacerbating oxidative stress. Intravenous (iv) iron, that is used to...

Cite
Nuhu F, Seymour AM, Bhandari S. Impact of Intravenous Iron on Oxidative Stress and Mitochondrial Function in Experimental Chronic Kidney Disease. Antioxidants (Basel). 2019;8(10)doi: 10.3390/antiox8100498.
Nuhu, F., Seymour, A. M., & Bhandari, S. (2019). Impact of Intravenous Iron on Oxidative Stress and Mitochondrial Function in Experimental Chronic Kidney Disease. Antioxidants (Basel, Switzerland), 8(10), . https://doi.org/10.3390/antiox8100498
Nuhu, Faisal, et al. "Impact of Intravenous Iron on Oxidative Stress and Mitochondrial Function in Experimental Chronic Kidney Disease." Antioxidants (Basel, Switzerland) vol. 8,10 (2019). doi: https://doi.org/10.3390/antiox8100498
Nuhu F, Seymour AM, Bhandari S. Impact of Intravenous Iron on Oxidative Stress and Mitochondrial Function in Experimental Chronic Kidney Disease. Antioxidants (Basel). 2019 Oct 21;8(10). doi: 10.3390/antiox8100498. PMID: 31640237; PMCID: PMC6826506.
Copy Download .nbib Format: NLM
Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.

Open forum infectious diseases

Bariola JR, McCreary EK, Wadas RJ, Kip KE, Marroquin OC, Minnier T, Koscumb S, Collins K, Schmidhofer M, Shovel JA, Wisniewski MK, Sullivan C, Yealy DM, Nace DA, Huang DT, Haidar G, Khadem T, Linstrum K, Seymour CW, Montgomery SK, Angus DC, Snyder GM.
PMID: 34250192
Open Forum Infect Dis. 2021 May 17;8(7):ofab254. doi: 10.1093/ofid/ofab254. eCollection 2021 Jul.

BACKGROUND: Monoclonal antibody treatment may prevent complications of coronavirus disease 2019 (COVID-19). We sought to quantify the impact of bamlanivimab monoclonal antibody monotherapy on hospitalization and mortality among outpatients at high risk of COVID-19 complications.METHODS: In this observational study...

Cite
Bariola JR, McCreary EK, Wadas RJ, et al. Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Open Forum Infect Dis. 2021;8(7):ofab254doi: 10.1093/ofid/ofab254.
Bariola, J. R., McCreary, E. K., Wadas, R. J., Kip, K. E., Marroquin, O. C., Minnier, T., Koscumb, S., Collins, K., Schmidhofer, M., Shovel, J. A., Wisniewski, M. K., Sullivan, C., Yealy, D. M., Nace, D. A., Huang, D. T., Haidar, G., Khadem, T., Linstrum, K., Seymour, C. W., Montgomery, S. K., Angus, D. C., & Snyder, G. M. (2021). Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Open forum infectious diseases, 8(7), ofab254. https://doi.org/10.1093/ofid/ofab254
Bariola, J Ryan, et al. "Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection." Open forum infectious diseases vol. 8,7 (2021): ofab254. doi: https://doi.org/10.1093/ofid/ofab254
Bariola JR, McCreary EK, Wadas RJ, Kip KE, Marroquin OC, Minnier T, Koscumb S, Collins K, Schmidhofer M, Shovel JA, Wisniewski MK, Sullivan C, Yealy DM, Nace DA, Huang DT, Haidar G, Khadem T, Linstrum K, Seymour CW, Montgomery SK, Angus DC, Snyder GM. Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Open Forum Infect Dis. 2021 May 17;8(7):ofab254. doi: 10.1093/ofid/ofab254. eCollection 2021 Jul. PMID: 34250192; PMCID: PMC8241472.
Copy Download .nbib Format: NLM
Launching a comparative effectiveness adaptive platform trial of monoclonal antibodies for COVID-19 in 21 days.

Contemporary clinical trials

McCreary EK, Bariola JR, Minnier T, Wadas RJ, Shovel JA, Albin D, Marroquin OC, Schmidhofer M, Wisniewski MK, Nace DA, Sullivan C, Axe M, Meyers R, Khadem T, Garrard W, Collins K, Wells A, Bart RD, Linstrum K, Montgomery SK, Haidar G, Snyder GM, McVerry BJ, Seymour CW, Yealy DM, Huang DT, Angus DC.
PMID: 34896293
Contemp Clin Trials. 2021 Dec 09;113:106652. doi: 10.1016/j.cct.2021.106652. Epub 2021 Dec 09.

Outpatient treatments that limit progression to severe coronavirus disease 2019 (COVID-19) are of vital importance to optimise patient outcomes and public health. Monoclonal antibodies (mAb) demonstrated ability to decrease hospitalizations in randomized, clinical trials. However, there are many barriers...

Cite
McCreary EK, Bariola JR, Minnier T, et al. Launching a comparative effectiveness adaptive platform trial of monoclonal antibodies for COVID-19 in 21 days. Contemp Clin Trials. 2021;113:106652doi: 10.1016/j.cct.2021.106652.
McCreary, E. K., Bariola, J. R., Minnier, T., Wadas, R. J., Shovel, J. A., Albin, D., Marroquin, O. C., Schmidhofer, M., Wisniewski, M. K., Nace, D. A., Sullivan, C., Axe, M., Meyers, R., Khadem, T., Garrard, W., Collins, K., Wells, A., Bart, R. D., Linstrum, K., Montgomery, S. K., Haidar, G., Snyder, G. M., McVerry, B. J., Seymour, C. W., Yealy, D. M., Huang, D. T., & Angus, D. C. (2021). Launching a comparative effectiveness adaptive platform trial of monoclonal antibodies for COVID-19 in 21 days. Contemporary clinical trials, 113106652. https://doi.org/10.1016/j.cct.2021.106652
McCreary, Erin K, et al. "Launching a comparative effectiveness adaptive platform trial of monoclonal antibodies for COVID-19 in 21 days." Contemporary clinical trials vol. 113 (2021): 106652. doi: https://doi.org/10.1016/j.cct.2021.106652
McCreary EK, Bariola JR, Minnier T, Wadas RJ, Shovel JA, Albin D, Marroquin OC, Schmidhofer M, Wisniewski MK, Nace DA, Sullivan C, Axe M, Meyers R, Khadem T, Garrard W, Collins K, Wells A, Bart RD, Linstrum K, Montgomery SK, Haidar G, Snyder GM, McVerry BJ, Seymour CW, Yealy DM, Huang DT, Angus DC. Launching a comparative effectiveness adaptive platform trial of monoclonal antibodies for COVID-19 in 21 days. Contemp Clin Trials. 2021 Dec 09;113:106652. doi: 10.1016/j.cct.2021.106652. Epub 2021 Dec 09. PMID: 34896293; PMCID: PMC8654455.
Copy Download .nbib Format: NLM
Launching a comparative effectiveness adaptive platform trial of monoclonal antibodies for COVID-19 in 21 days.

Contemporary clinical trials

McCreary EK, Bariola JR, Minnier T, Wadas RJ, Shovel JA, Albin D, Marroquin OC, Schmidhofer M, Wisniewski MK, Nace DA, Sullivan C, Axe M, Meyers R, Khadem T, Garrard W, Collins K, Wells A, Bart RD, Linstrum K, Montgomery SK, Haidar G, Snyder GM, McVerry BJ, Seymour CW, Yealy DM, Huang DT, Angus DC.
PMID: 34896293
Contemp Clin Trials. 2021 Dec 09;113:106652. doi: 10.1016/j.cct.2021.106652. Epub 2021 Dec 09.

Outpatient treatments that limit progression to severe coronavirus disease 2019 (COVID-19) are of vital importance to optimise patient outcomes and public health. Monoclonal antibodies (mAb) demonstrated ability to decrease hospitalizations in randomized, clinical trials. However, there are many barriers...

Cite
McCreary EK, Bariola JR, Minnier T, et al. Launching a comparative effectiveness adaptive platform trial of monoclonal antibodies for COVID-19 in 21 days. Contemp Clin Trials. 2021;113:106652doi: 10.1016/j.cct.2021.106652.
McCreary, E. K., Bariola, J. R., Minnier, T., Wadas, R. J., Shovel, J. A., Albin, D., Marroquin, O. C., Schmidhofer, M., Wisniewski, M. K., Nace, D. A., Sullivan, C., Axe, M., Meyers, R., Khadem, T., Garrard, W., Collins, K., Wells, A., Bart, R. D., Linstrum, K., Montgomery, S. K., Haidar, G., Snyder, G. M., McVerry, B. J., Seymour, C. W., Yealy, D. M., Huang, D. T., & Angus, D. C. (2021). Launching a comparative effectiveness adaptive platform trial of monoclonal antibodies for COVID-19 in 21 days. Contemporary clinical trials, 113106652. https://doi.org/10.1016/j.cct.2021.106652
McCreary, Erin K, et al. "Launching a comparative effectiveness adaptive platform trial of monoclonal antibodies for COVID-19 in 21 days." Contemporary clinical trials vol. 113 (2021): 106652. doi: https://doi.org/10.1016/j.cct.2021.106652
McCreary EK, Bariola JR, Minnier T, Wadas RJ, Shovel JA, Albin D, Marroquin OC, Schmidhofer M, Wisniewski MK, Nace DA, Sullivan C, Axe M, Meyers R, Khadem T, Garrard W, Collins K, Wells A, Bart RD, Linstrum K, Montgomery SK, Haidar G, Snyder GM, McVerry BJ, Seymour CW, Yealy DM, Huang DT, Angus DC. Launching a comparative effectiveness adaptive platform trial of monoclonal antibodies for COVID-19 in 21 days. Contemp Clin Trials. 2021 Dec 09;113:106652. doi: 10.1016/j.cct.2021.106652. Epub 2021 Dec 09. PMID: 34896293; PMCID: PMC8654455.
Copy Download .nbib Format: NLM
Microbiome Shifts Associated With the Introduction of Wild Atlantic Horseshoe Crabs (.

Frontiers in microbiology

Friel AD, Neiswenter SA, Seymour CO, Bali LR, McNamara G, Leija F, Jewell J, Hedlund BP.
PMID: 32765431
Front Microbiol. 2020 Jul 14;11:1398. doi: 10.3389/fmicb.2020.01398. eCollection 2020.

The Atlantic horseshoe crab (

Cite
Friel AD, Neiswenter SA, Seymour CO, et al. Microbiome Shifts Associated With the Introduction of Wild Atlantic Horseshoe Crabs (. Front Microbiol. 2020;11:1398doi: 10.3389/fmicb.2020.01398.
Friel, A. D., Neiswenter, S. A., Seymour, C. O., Bali, L. R., McNamara, G., Leija, F., Jewell, J., & Hedlund, B. P. (2020). Microbiome Shifts Associated With the Introduction of Wild Atlantic Horseshoe Crabs (. Frontiers in microbiology, 111398. https://doi.org/10.3389/fmicb.2020.01398
Friel, Ariel D, et al. "Microbiome Shifts Associated With the Introduction of Wild Atlantic Horseshoe Crabs (." Frontiers in microbiology vol. 11 (2020): 1398. doi: https://doi.org/10.3389/fmicb.2020.01398
Friel AD, Neiswenter SA, Seymour CO, Bali LR, McNamara G, Leija F, Jewell J, Hedlund BP. Microbiome Shifts Associated With the Introduction of Wild Atlantic Horseshoe Crabs (. Front Microbiol. 2020 Jul 14;11:1398. doi: 10.3389/fmicb.2020.01398. eCollection 2020. PMID: 32765431; PMCID: PMC7381184.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 113 entries